pramipexol eg 0.52 mg tabl. verl. afgifte
eg sa-nv - pramipexoldihydrochloridemonohydraat 0,75 mg - eq. pramipexol 0,52 mg - tablet met verlengde afgifte - 0,52 mg - pramipexoldihydrochloridemonohydraat 0.75 mg - pramipexole
pramipexol eg 1.05 mg tabl. verl. afgifte
eg sa-nv - pramipexoldihydrochloridemonohydraat 1,5 mg - eq. pramipexol 1,05 mg - tablet met verlengde afgifte - 1,05 mg - pramipexoldihydrochloridemonohydraat 1.5 mg - pramipexole
pramipexol eg 1.57 mg tabl. verl. afgifte
eg sa-nv - pramipexoldihydrochloridemonohydraat 2,25 mg - eq. pramipexol 1,57 mg - tablet met verlengde afgifte - 1,57 mg - pramipexoldihydrochloridemonohydraat 2.25 mg - pramipexole
pramipexol eg 2.1 mg tabl. verl. afgifte
eg sa-nv - pramipexoldihydrochloridemonohydraat 3 mg - eq. pramipexol 2,1 mg - tablet met verlengde afgifte - 2,10 mg - pramipexoldihydrochloridemonohydraat 3 mg - pramipexole
pramipexol eg 2.62 mg tabl. verl. afgifte
eg sa-nv - pramipexoldihydrochloridemonohydraat 3,75 mg - eq. pramipexol 2,62 mg - tablet met verlengde afgifte - 2,62 mg - pramipexoldihydrochloridemonohydraat 3.75 mg - pramipexole
pramipexol eg 3.15 mg tabl. verl. afgifte
eg sa-nv - pramipexoldihydrochloridemonohydraat 4,5 mg - eq. pramipexol 3,15 mg - tablet met verlengde afgifte - 3,15 mg - pramipexoldihydrochloridemonohydraat 4.5 mg - pramipexole
pramipexole eg 0.18 mg tabl.
eg sa-nv - pramipexoldihydrochloridemonohydraat 0,25 mg - eq. pramipexol 0,18 mg - tablet - 0,18 mg - pramipexoldihydrochloridemonohydraat - pramipexole
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastische middelen - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - carcinoom, niet-kleincellige long - antineoplastische middelen - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinoom, niet-kleincellige long - antineoplastische middelen - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.